

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 26 Apr 2020 18:14:04 +0000  
**To:** Gibbons, Gary (NIH/NHLBI) [E]  
**Cc:** Koroshetz, Walter (NIH/NINDS) [E]; (b) (6); Auchincloss, Hugh (NIH/NIAID) [C]; (b) (6); Collins, Francis (NIH/OD) [E]; (b) (6); Tabak, Lawrence (NIH/OD) [E]; Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]  
**Subject:** Thrombotic phenomena in COVID-19

Gary:

In follow-up of our recent conversation regarding the growing evidence that the extremely catastrophic course of many patients with COVID-19 seems to me pathogenically associated with the findings of microthrombi in the lungs and often a multisystem process resembling DIC. In addition, there have been growing numbers of cases of individuals (some young and otherwise healthy) who have had unexplained strokes, only to find out that they actually have COVID-19. (b) (5)

(b) (5)

(b) (5) Thanks.

Best,  
Tony

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 26 Apr 2020 17:42:12 +0000  
**To:** NIAID OD AM  
**Subject:** FW: Invitation to Webinar as keynote speaker.

I wouldn't think so.

**From:** Secretary ARP [REDACTED] (b) (6)>  
**Sent:** Saturday, April 25, 2020 2:07 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)  
**Subject:** Invitation to Webinar as keynote speaker.

To,  
Anthony S. Fauci,  
Office of the Director,  
National Institute of Allergy and Infectious Diseases,  
National Institutes of Health, 9000 Rockville Pike, Bldg 31, Room 7A03,  
Bethesda MD 20892

Subject: Invitation to Webinar as keynote speaker.

Dear Sir,

On behalf of ASSOCIATION OF REGISTERED PHARMACIST (An association working for Pharmacy Profession and having more than 2000 members) in collaboration with Divine International, Gwalior (A Pioneer Pharmacy Institute) I am pleased to invite you to our Webinar having THEME "CHALLENGES AND OPPORTUNITIES FOR PHARMACIST IN THE PRESENT EPIDEMIC COVID-19" that will be held from 2nd May 2020 to 3rd May 2020. This Webinar is the get together of Pharma professionals through the web. The vision of this Webinar is to Aware, Prepare and strengthen our Pharmacy professionals in our country to this epidemic COVID-19 for present and future aspect and exports more realistic ideas and present scenario of this epidemic COVID-19.

You are one of the legends of Pharma Expert of our country, it is a great privilege for us to see if you share your experience with us, we really expect and want that you join our Webinar and share with us the great experience of your life, we want to learn something from you so that we can create a great ideas, opportunity, and roll of Pharma professional for our country in the present scenario.

We would be pleased to have you present at this point at this webinar to listen to what the role and importance in the Pharmacist advancement and their impact on our society and daily life we would also love to hear your thoughts and opinion about the Pharma professional that is a dream of our pharmacy fraternity.

Therefore you are requested to send your recorded Lecture/presentation of 30-40 min

Sincerely,

--  
Thanks

**Rajesh Singh Jadon**  
Secretary (National)  
Association of Registered Pharmacists  
Gwalior MP  
Mob: [REDACTED] (b) (6)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 26 Apr 2020 15:43:25 +0000  
**To:** [REDACTED] (b) (6)  
**Subject:** RE [REDACTED] (b) (6), (b) (4)  
**Attachments:** [REDACTED] (b) (6), (b) (4)

---

**From:** [REDACTED] (b) (6) >  
**Sent:** Sunday, April 26, 2020 11:32 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)  
**Subject:** FW: [REDACTED] (b) (6), (b) (4)

To work on at home

---

**From:** Ulrich, Connie M [REDACTED] (b) (6)  
**Sent:** Saturday, April 25, 2020 2:35 PM  
**To:** Cynda Rushton [REDACTED] (b) (6) >; [REDACTED] (b) (6)  
**Subject:** [REDACTED] (b) (6), (b) (4)

Hi Christine and Cynda,

I finished my section and unfortunately have to keep changing the COVID numbers! I will add some thoughts to the last section. Not sure how much we can add there but maybe some reflections would be helpful. Enjoy the sunshine today!!

Best,  
Connie

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 26 Apr 2020 02:57:31 +0000  
**To:** Collins, Francis (NIH/OD) [E]  
**Cc:** Tabak, Lawrence (NIH/OD) [E]  
**Bcc:** Mascola, John (NIH/VRC) [E] (b) (6)  
**Subject:** RE: agenda for Kadlec et al., Sun noon meeting

Francis:

Sorry that I took so long to respond.

(b) (5)

(b) (5)

(b) (5) Let us connect

by phone first thing in the AM>

Thanks,

Tony

---

**From:** Collins, Francis (NIH/OD) [E] <(b) (6)>  
**Sent:** Saturday, April 25, 2020 2:55 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Tabak, Lawrence (NIH/OD) [E] <(b) (6)>  
**Subject:** RE: agenda for Kadlec et al., Sun noon meeting

(b) (5)

---

**From:** Collins, Francis (NIH/OD) [E]  
**Sent:** Saturday, April 25, 2020 2:49 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Tabak, Lawrence (NIH/OD) [E] <(b) (6)>  
**Subject:** agenda for Kadlec et al., Sun noon meeting

Hi Tony and Larry,

For the meeting tomorrow at noon (currently invitees are Kadlec, Disbrow, Johnson, Woodcock, Marks, and us three), I would propose the following framework:

(b) (5)



Thoughts? Tony, should  (b) (5)

Francis

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 26 Apr 2020 01:22:21 +0000  
**To:** Corey MD, Larry  
**Cc:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** RE: [REDACTED] (b) (6)

Let us talk tomorrow (Sunday). I am sorry that I did not get back to you today.

---

**From:** Corey MD, Larry [REDACTED] (b) (6)  
**Sent:** Saturday, April 25, 2020 5:36 PM  
**To:** Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6) >  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6); Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6)  
**Subject:** Re: [REDACTED] (b) (6)

Agree. [REDACTED] (b) (6)

Sent from my iPhone

On Apr 25, 2020, at 1:59 PM, Mascola, John (NIH/VRC) [E] <[REDACTED] (b) (6)> wrote:

[REDACTED] (b) (6) seem reasonable

Sent from my iPhone

On Apr 25, 2020, at 15:54, Corey MD, Larry [REDACTED] (b) (6) wrote:


A do have to say I am surprised . but ok

---

**From:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >  
**Sent:** Saturday, April 25, 2020 12:53 PM  
**To:** Corey MD, Larry [REDACTED] (b) (6); Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6) >  
**Cc:** Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) >  
**Subject:** Fwd: New England Journal of Medicine 20-13479

Let us discuss next steps

Begin forwarded message:





**From:** (b) (6)  
**Sent:** Sat, 25 Apr 2020 13:05:04 -0400  
**To:** Collins, Francis (NIH/OD) [E]  
**Cc:** Tabak, Lawrence (NIH/OD) [E]  
**Subject:** Re: White House Task Force Briefing Monday

(b) (5)

On Apr 25, 2020, at 11:42 AM, Collins, Francis (NIH/OD) [E]

<(b) (6)>

Judy Stecker called. Said there's a separate (b)(5) - PCP

(b) (5)

(b) (5)

(b) (5)

FC

---

**From:** Collins, Francis (NIH/OD) [E]  
**Sent:** Saturday, April 25, 2020 10:36 AM  
**To:** (b) (6)(OS/IOS) (b) (6)  
**Cc:** Tabak, Lawrence (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAD) [E] <(b) (6)>; Pence, Laura (HHS/ASL) <(b) (6)>; Harrison, Brian (HHS/IOS) (b) (6)>; Wood, Gretchen (NIH/OD) [E] (b) (6) McManus, Ayanna (NIH/OD) [E] (b) (6)  
**Subject:** FW: White House Task Force Briefing Monday


Hi Mr. Secretary,

Please see below for a (b)(5) - PCP


(b) (5) Glad to speak with you about how best to handle, if you have advice. (b) (6)

Francis

(b)(5) - PCP







**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 24 Apr 2020 14:25:16 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** FW: Italy Covid-19

La Stampa is one of the two most important newspapers in Italy.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Mastrolilli Paolo <Paolo.MASTROLILLI@lastampa.it>  
**Sent:** Friday, April 24, 2020 10:08 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** Italy Covid-19

Dear Doctor Fauci,

My name is Paolo Mastrolilli, I am the US Bureau Chief for the Italian daily La Stampa. I am writing because we would appreciate very much the opportunity to have a phone or written Q&As interview with you to discuss the Covid 19 pandemic. Considering the difficult situation Italy is experiencing, the help President Trump is sending to Italy, and the plan to open America again, it would be very helpful for Italy to hear from your experience and competence to address the Covid 19. We think that your advices would be very helpful to help our country and our citizens in dealing with the pandemic.

We understand that you are very busy and this request has no deadline.

La Stampa is a leading Italian daily, it is owned by the Agnelli Elkann family, owner of Fiat Chrysler as well.

I am also a contributor for the Vatican Radio and the official news portal of the Holy See, I would share the interview with them as well, if you like.

My cellphone number is (b) (6)

Please let me know if you need any further information.

Best regards

Paolo Mastrolilli

---

Il presente messaggio (inclusi gli allegati) contiene informazioni riservate esclusivamente al destinatario/ai destinatari indicato/i nel messaggio, ed è protetto dalla legge. La diffusione, distribuzione e/o la copia del contenuto del presente messaggio da parte di qualsiasi soggetto diverso dal destinatario è severamente vietata ai sensi dell'art. 616 c.p. e delle vigenti normative in materia di protezione dei dati personali. Se non siete i destinatari del presente messaggio, vi preghiamo di distruggerlo e di darcene immediata comunicazione inviando un messaggio di ritorno all'indirizzo e-mail del mittente.

This message (including any attachments) contains confidential information intended only for the recipient(s) named above, and is protected by law. Any disclosure, distribution and/or copying of this message by any subject different from the named recipient(s) is strictly prohibited according to art. 616 c.p. and to the applicable data protection laws. If you are not the intended recipient, please delete this message and inform us immediately about the deletion by sending a message to the sender's e-mail address.

---

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 24 Apr 2020 10:33:49 +0000  
**To:** Holland, Steven (NIH/NIAID) [E]  
**Cc:** Marston, Hilary (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]  
**Subject:** RE: Successful Submission of a Manuscript to Science (abc4208)

Thanks, Steve.

-----Original Message-----

**From:** Holland, Steven (NIH/NIAID) [E] (b) (6)  
**Sent:** Thursday, April 23, 2020 11:48 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Cc:** Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6)  
**Subject:** FW: Successful Submission of a Manuscript to Science (abc4208)

This is the acalabrutinib paper today submitted to Science. NEJM was interested but wanted a month delay to be sure about the results but some of the authors (Not the NIAID one) balked and have gone elsewhere. Just keeping you in the loop.

Steve

--

Director, Division of Intramural Research National Institute of Allergy and Infectious Diseases National Institutes of Health  
Bldg. 10/11N248 MSC 1960  
Bethesda, MD 20892-1960  
(b) (6) voice  
301-480-4507 fax  
(b) (6)

Assistant lab: Eva Portillo  
(b) (6)  
(b) (6) voice

Assistant to SD: Beth Schmidt  
(b) (6)  
(b) (6) voice

On 4/23/20, 1:59 PM, "Lionakis, Michail (NIH/NIAID) [E]" (b) (6) > wrote:

Attached the submitted paper, which will be deposited to MedRxiv.org today I think.  
Mihalís

On 4/23/20, 1:34 PM, "science\_editors@aaas.org" <science\_editors@aaas.org> wrote:

Manuscript Title: Inhibition of Bruton Tyrosine Kinase in Patients with Severe Covid-19  
Author: Lionakis  
Manuscript Number: abc4208

Dear Dr. Lionakis:

You are listed as a coauthor on the above manuscript, which has recently been submitted to Science.

According to Science policy, all authors must have seen and approved the submission of their manuscript. If you have seen the manuscript and approved its submission, no action is necessary.

If you have not read this paper or do not approve its submission to Science, please let us know as soon as possible. Please refer to the manuscript number listed above in any correspondence (you can just reply to this message).

You can see the status of your manuscript at any time by logging into your account at the Science Journals Submission and Information Portal at <https://cts.sciencemag.org>.

If you do not yet have an account, please go to <https://cts.sciencemag.org/scc/#/forgot-password> and use the email at which you received this correspondence because that is linked to your manuscript. Then, follow the prompts to set your password and login. After login, you can access your manuscript and monitor its status.

Once you are registered, we encourage you to link your account to your ORCID ID, an identifier that facilitates the correct attribution of your publications to you. To learn more about ORCID or to obtain an ORCID ID, visit their site at: <http://orcid.org>.

Your manuscript is now undergoing an initial screening to determine whether it will be sent for in-depth review. If the manuscript is sent to review, its status will change to "To Review".

Sincerely,  
The Editors  
Science



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 24 Apr 2020 01:58:36 +0000  
**To:** Greg Folkers (b) (6)  
**Subject:** FW: HIVR4P postponed to 17-21 January 2021

FYI. See yellow highlighted request.

**From:** HIVR4P - Secretariat <secretariat@hivr4p.org>  
**Sent:** Thursday, April 23, 2020 11:23 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Cc:** Conrad, Patricia (NIH/NIAID) [E] (b) (6); Dieffenbach, Carl (NIH/NIAID) [E] (b) (6) >  
**Subject:** HIVR4P postponed to 17-21 January 2021



Dear Dr. Fauci,

As the research community responds to the global challenges of the COVID-19 pandemic, HIV prevention science matters as much as ever. Our priority as organizers of the HIV Research for Prevention (HIVR4P) conference remains the safety and wellbeing of all participants.

After careful consideration, we have decided to postpone the HIVR4P conference to **17-21 January 2021**. Updated details for the session(s) are listed below:

<b>Session title:</b>	HIV prevention 2020 – Where are we now and where are we going?
<b>Session type:</b>	Opening plenary
<b>Suggested presentation title/topic:</b>	Much accomplished; Much to do – An overview on HIV prevention research
<b>Session description:</b>	Today's plenary sets the stage for the conference week ahead, outlining the big-picture challenges we face in research, product development and access to prevention. Speakers will provide diverse perspectives on the state of the field today, the opportunities and obstacles ahead and priorities for action moving forward.
<b>Session date and time:</b>	<b>Monday, 18 January 2021 - 16:00-18:00</b>

#### **Meet the Experts lunches**

We invite you to host an informal table discussion at a Meet the Experts lunch on **20 January 2021, 12:00-13:00**. Daily meet the experts lunches provide early-career investigators and community advocates with valuable opportunities for informal, in-depth exchange with experts representing a cross-section of research issues, implementation challenges and HIV-affected communities.

Please reply to this email by Wednesday, 6 May if you are still available to deliver this important presentation and, if so, please also include a photo and a brief biography.

We are acutely aware many researchers and research organizations with critical studies and submissions to HIVR4P are now also heavily engaged in the COVID-19 response. Our hope is that postponing the conference, rather than presenting it virtually in October, will allow for the broadest participation to foster knowledge-exchange, debate and direction-setting in the field of HIV prevention research that HIVR4P is known for.

Thank you for your consideration.

Sincerely,

HIVR4P - Secretariat  
HIV Research for Prevention

W: [REDACTED] (b) (6)  
Avenue de France 23 | CH-1202 Geneva | Switzerland

**HIVR4P Conference | 17-21 January 2021 | Cape Town, South Africa**



[HIVR4P.org](http://HIVR4P.org)



[@HIVR4Px](https://twitter.com/HIVR4Px)



[/HIVR4P](https://www.facebook.com/HIVR4P)

---

**From:** HIVR4P - Secretariat

**Sent:** 21 February 2020 16:57

**To:** [REDACTED] (b) (6)

**Cc:** Bargavi Thyagarajan [REDACTED] (b) (6)

**Subject:** HIVR4P 2020 - Invitation to present



HIV RESEARCH  
FOR PREVENTION

CAPE TOWN, SOUTH AFRICA - 11-15 OCTOBER 2020

Dear Dr. Fauci,

We are writing with great pleasure to invite you to present at the 4th HIV Research for Prevention Conference ([HIVR4P 2020](#)) in Cape Town, South Africa, from 11-15 October 2020. HIV Research for Prevention is the only global scientific conference focused exclusively on the challenging and fast-growing field of HIV prevention research. HIVR4P fosters interdisciplinary knowledge-exchange on HIV vaccines, microbicides, PrEP, treatment as prevention and biomedical interventions as well as their related social and behavioural implications.

Details for the session(s) are listed below:

<b>Session title:</b>	HIV prevention 2020 – Where are we now and where are we going?
<b>Session type:</b>	Opening plenary
<b>Suggested presentation title/topic:</b>	Much accomplished; Much to do – An overview on HIV prevention research
<b>Session description:</b>	Today's plenary sets the stage for the conference week ahead, outlining the big-picture challenges we face in research, product development and access to prevention. Speakers will provide diverse perspectives on the state of the field today, the opportunities and obstacles ahead and priorities for action moving forward.
<b>Session date and time:</b>	Monday, 12 October 2020 - 16:00-18:00

### Meet the Experts lunches

We invite you to host an informal table discussion at a Meet the Experts lunch on **14 October 2020, 12:00-13:00**. Daily meet the experts lunches provide early-career investigators and community advocates with valuable opportunities for informal, in-depth exchange with experts representing a cross-section of research issues, implementation challenges and HIV-affected communities.

As an invited-speaker, you would be eligible to receive:

- Complimentary conference registration;
- Roundtrip economy airfare arranged through the HIVR4P travel agency; and
- Accommodation at one of the hotels pre-blocked by the conference secretariat.

To accept this invitation, please reply to this email by **Thursday, 27 February** and include a photo and a brief biography. Please find also attached for your record the official invitation signed by the HIVR4P 2020 Co-Chairs.

We ask that you please send any questions to the HIVR4P Secretariat at [secretariat@hivr4p.org](mailto:secretariat@hivr4p.org).

Thank you for your consideration. We look forward to you joining us in Cape Town!

Sincerely,

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 24 Apr 2020 01:30:49 +0000  
**To:** blonda quirico  
**Subject:** RE: estimation of dynamics of COVID-19 in USA new simulations at 23 April 2020

Thanks.

---

**From:** blonda quirico <[REDACTED] (b) (6)>  
**Sent:** Thursday, April 23, 2020 5:02 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>; COPPIETERS'T WALLANT Yves [REDACTED] (b) (6)>  
**Subject:** estimation of dynamics of COVID-19 in USA new simulations at 23 April 2020

Tony,

We send you our simulations.

Best regards.

Quirico

Le mercredi 22 avril 2020 à 00:09:50 UTC+2, Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)> a écrit :

Thanks.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: [REDACTED] (b) (6)  
FAX: (301) 496-4409  
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** blonda quirico (b) (6)  
**Sent:** Tuesday, April 21, 2020 11:18 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6); COPPIETERS' WALLANT Yves (b) (6) >  
**Subject:** Re: estimation of dynamics of COVID-19 in USA new simulations at 21 April 2020

Tony,

Professor COPPIETERS and I, we send you our new simulations :

In summary, the USA COVID-19 epidemic model says :

- the final size of epidemic = more than 850610 people infected and detected;
- date of epidemic peak = +/- 7 April 2020 with theoretical new cases - in one day during this peak - about +/- 35520;
- end of epidemic = +/- 19-28 June 2020 (we use two methods);
- mortality at the end of epidemic :
- \*\* if death rate 5% = +/- 42.530 deceased people (for the moment the death rate = 5%)
- \*\* if death rate 10% = +/- 85.060 deceased people

You reached 91,1 % of the theoretical logistic curve.

Best regards.

Quirico

00 32 475 48 68 42

Le dimanche 19 avril 2020 à 15:57:50 UTC+2, Fauci, Anthony (NIH/NIAID) [E] (b) (6) > a écrit :

Quirico:

Thanks again! Please keep this information coming to me.

Best regards,

Tony

---

**From:** blonda quirico (b) (6) >  
**Sent:** Sunday, April 19, 2020 5:04 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; COPPIETERS'T WALLANT Yves (b) (6)  
**Subject:** Re: estimation of dynamics of COVID-19 in USA new simulations at 18 April 2020

Tony,

We send you our new simulations.

In summary, the USA COVID-19 epidemic model says :

- the final size of epidemic = more than 779000 people infected and detected;
- date of epidemic peak = +/- 7 April 2020 with theoretical new cases - in one day during this peak - about +/- 35063;
- end of epidemic = +/- 4-13 June 2020 (we use two methods);

- mortality at the end of epidemic :

\*\* if dead rate 5% = +/- 40000 deceased people

\*\* if dead rate 10% = +/- 80.000 deceased people

You reached 87.5 % of the theoretical logistic curve.

Best regards.

Quirico

00 32 475 48 68 42

Le lundi 6 avril 2020 à 03:32:35 UTC+2, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> a écrit :

Dr. Blonda:

Thank you for sending me this information. I appreciate it.

Best regards,

Tony

---

**From:** blonda quirico (b) (6)  
**Sent:** Sunday, April 5, 2020 9:23 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; COPPIETERS' WALLANT Yves (b) (6)>  
**Subject:** estimation of dynamics of COVID-19 in USA

Professor Anthony FAUCY,

Sorry to disturb during the COVID-19 in USA.

But I would you inform about the COVID-19 in USA.

I'm medical doctor in Belgium.

With my teacher Professor Yves COPPIETERS ( Ecole de santé publique - ULB - Brussels), we make simulations about the COVID-19 for many countries.

In summary, the USA COVID-19 epidemic model says :

- the final size of epidemic = +/- 462760 people infected and detected;
- date of epidemic peak = +/- 1- 2 April 2020 with theoretical new cases - in one day during this peak - about +/- 28390;
- end of epidemic = +/- 15 May 2020;
- mortality :
- \*\* if dead rate 5% = +/- 23140 deceased people
- \*\* if dead rate 10% = +/- 46275 deceased people

If you are interested by our simulations, you can contact us.

Best regards.

Dr Quirico BLONDA

(b) (6)



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 24 Apr 2020 00:50:12 +0000  
**To:** [REDACTED] (b) (6)  
**Subject:** FW: The Tablet I find myself thinking back to his father, Stephen Fauci, whose drugstore our family relied on back in the 1950s.

You have got to read this!!!

**From:** Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)>  
**Sent:** Thursday, April 23, 2020 7:21 PM  
**To:** NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>  
**Subject:** The Tablet I find myself thinking back to his father, Stephen Fauci, whose drugstore our family relied on back in the 1950s.

<https://thetablet.org/only-in-print-dr-faucis-roots-in-dyker-heights/>

[ADVERTISE](#) | [CLASSIFIEDS](#) | [CONTACT US](#)

# THE TABLET

**GO**

NEWS

OPINION

PARISHES

SCHOOLS

SPORTS

AROUND THE DIOCESE

STAY HOME

CORONAVIRUS

## Only in Print: Dr. Fauci's Roots in Dyker Heights

April 8, 2020



*Dr. Anthony Fauci meets with Regis High School students and the school's president, Father Daniel Lahart S.J., in 2019. Fauci (whose family owned a neighborhood pharmacy in Dyker Heights) is a 1958 graduate of the Jesuit school. (Photo: courtesy of Fauci family)*

### CATHOLIC NEWS SERVICE

Religious education continues in different format during pandemic

Bishops in Amazon urge Peru to guard indigenous needs during pandemic

April 15, 2020  
Volume 15

## **From the Neighborhood** by Frank Derosa

Frank DeRosa retired as Associate Publisher of The Tablet and director of the Diocesan Public Information Office in 2008

**When I see Dr. Anthony Fauci on the TV screen explaining expertly everything we need to know about the coronavirus pandemic, I find myself thinking back to his father, Stephen Fauci, whose drugstore our family relied on back in the 1950s.**

**Steve Fauci was the neighborhood pharmacist.**

**The Fauci Pharmacy stood on the southwest corner of 13 th Ave. and 83 rd St., in the Dyker Heights section of Brooklyn, diagonally across from the Shrine Church of St. Bernadette. We lived two blocks away on 85 th .**

Long ago parishioners like me remember what the store looked like, the soda fountain that ran along the right wall, the telephone booths at the left close to the entrance and the counter straight ahead down the center.

Whenever my mother sent me there, Mr. Fauci would be behind the counter, but it was a family enterprise. They lived in an apartment above the store, and if the patriarch wasn't serving you, his wife, Eugenia, or daughter, Denise, was there. Young Anthony, I've since learned, pitched in too, his father sending him out on his bike to deliver items to customers.

I've never met the man who has become the most important medical voice in the country. Nor have former parishioners that I've spoken to about him in recent days, like boyhood pals Anthony LoFrisco, from 80th St., now in Connecticut, and Bob Orlando, who lived on 84th, now a New Jersey resident, as well as Bishop Gerald Barbarito of the Palm Beach Diocese, from 11th Ave. But each remembers the pharmacy as a Dyker Heights institution.

While we don't know him personally, in a sense he's become everyone's friend. With his steady television presence, he's imparted his vast knowledge and straightforward advice in a trademark, sometimes gravelly or raspy, Brooklyn accent that has endeared him to people far and wide. You can't be anything but proud of someone of his prominence who came from the parish.

Anthony became known as Tony, as he tells it, when Father Flanagan, principal of Regis High School, decided to call him that on his first day as a freshman. The name stuck.

Tony took buses and trains to the Jesuit school in Manhattan, including the old Sea Beach Express. He traveled 70 minutes each way, did three hours of homework, captained the basketball team and excelled in the classroom.

I remember hearing that when Tony was a high schooler, he had a part-time job working in St. Bernadette's rectory, answering the phone and doing whatever else parishioners wanted him to do to put them in touch with one of the parish priests. In those days, the rectory had a priestly bonanza. There

were four of them.

Because St. Bernadette's School had not yet been established, Tony went to Our Lady of Guadalupe School, where he was taught by Dominican Sisters. It was, and is, St. Bernadette's neighboring parish.

Like most kids, he loved sports. He played CYO baseball and basketball. At Dyker Park on 86th St., he and his friends developed skills in imitation of their heroes. A Yankee follower living in the midst of Brooklyn Dodgers fans who adored The Boys of Summer, he's said his favorite players were Joe DiMaggio and Mickey Mantle.

Tony's father and mother married at 18, after they graduated from New Utrecht High School. Steve went on to Columbia to study pharmacy.

Sometime after he opened his pharmacy, he became friends with Father Al Varriale, one of St. Bernadette's beloved parish priests. At one point, Steve, as a parent, and the priest known as Father V, who directed the parish's robust CYO sports program for youths, shared a concern. It was the easy availability of indecent

and immoral publications that they knew was a threat to the moral development of young people.

So, with the approval and support of the Diocese of Brooklyn, together they formed a diocesan commission against pornography. Both men are now long gone, and so is the commission, but it was a good idea, though it did not survive them.

Remarkably, just a few houses up the block from where Steve established his pharmacy, lived the Pellegrinos, another family of St. Bernadette's parishioners that produced a renowned medical professional. The eldest son, Edmund, became a bioethicist, a "preeminent" one, as one newspaper described him after he died. But he was more. He helped develop medical programs at Kentucky, Stony Brook and Tennessee Universities. Later, he took on the presidency of The Catholic University of America. Then, after completing his tenure there, he became, as physician and philosopher, the director of the Kennedy Institute of Ethics at Georgetown University.

Though years apart in age, both Dr. Fauci and Dr. Pellegrino became Hippocratic stars, nurtured on the same block.

**Only in Brooklyn, I say, not without bias.**

**Steve Fauci was known by members of his extended family and friends for his personality, kindness, sense of humor and wit, and for telling good stories. So they said in comments after he died in 2008.**

**Tony appears to have inherited Steve's gene for lightheartedness. His daughter once told the Washington Post that her dad could be a "goofball. . .he works hard and does his thing, but he comes home and he's singing opera in the kitchen and dancing around."**

**That kind of calm can help a man maintain his balance as he deals with the pressure of talking to millions of people every day about the complexity of a global pandemic.**

**As one newsman said, "When Fauci appears on the screen, you turn up the volume."**

**He once said the Jesuits at Regis and Holy Cross College taught him the importance of "precision of thought and economy of expression."**



**That's what he delivers every day: accurate information given concisely.**

**That's Tony Fauci, now a national treasure. And to think, he came from the neighborhood.**

### **Dr. Anthony Fauci**



He graduated from Regis High School and the College of Holy Cross. He graduated number one in his class at Cornell Medical School in 1966.

He completed his medical residency at New York Hospital. In 1984, he became director of National Institute of Allergy and Infectious Diseases, a position he holds today.



Front row, kneeling





**Stephen A. Fauci**

New Utrecht High School

Dante Circle  
*Vox Populi*

Steve was once known as the champ city sprinter, now he excels as the class great jester. A regular fellow with a ready smile and full of spirit. You could always count on Steve being present at every class and school affair.

**Disclaimer:** Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 24 Apr 2020 00:35:33 +0000  
**To:** Lerner, Andrea (NIH/NIAID) [E]  
**Subject:** FW: Another Possible Tool in The Fight Against SARS-CoV-2 ?

Please take a look and figure out where to send it.

**From:** Gary Radin <GRadin@dhs.lacounty.gov>  
**Sent:** Thursday, April 23, 2020 8:31 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** Another Possible Tool in The Fight Against SARS-CoV-2 ?

Dr. Fauci---Forgive the crude and unsolicited manner in which I am attempting to reach out to you but I don't really KNOW any other way !

I am not a medical doctor nor am I a principle investigator. I am just a Cytologist employed in the Anatomic Pathology department at LA County-USC Medical Center here in Southern California.

But I have been reading a lot--- and in my own exploration I have come across several articles which suggest the possibility of using a class of agents called SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS in combination with antivirals like oseltamivir (or perhaps Remdesivir?) to treat both the viral pathogen responsible for the current pandemic as well as the runaway immune response of the host leading to the oft fatal cytokine storms.

Apparently these compounds have been approved for flare-ups of multiple sclerosis, and have even been tried on Alzheimer's patients. The commonly known drug is FINGOLIMOD. But these papers that I have cited for you below seem to indicate that structural analogs of this compound could be important in damping down the dysregulated pro-inflammatory cascades which seem to be leading to DIC, alveolar exudates and diffuse alveolar damage, capillary leak syndrome and ultimately the multiple organ failure that is killing an unacceptably high number of people.

The fly in the ointment Dr. Fauci here is that these S-1-PR agonists have only been demonstrated to be effective in non-human primates and other mammals. And much of these studies on these compounds has been done not on coronaviruses but on influenza viruses. So it would be a gamble. But is that not how we have learned much about human health and disease is by the gracious sacrifice of our animal cousins ? And might it not be a general effect that these sphingosine derivatives have on viral sepsis so that maybe what works for influenza might work for the coronavirus?

In the dire situation that many of the most critically ill COVID 19 patients find themselves, it seems they are on the precipice of a rapid demise once they begin to show certain key laboratory results---(spikes in D-DIMER, C-Reactive Protein, Serum Ferritin, prolongation of

prothrombin and APTT, increased cardiac troponin 1, surges in IL-6, IL-7, monocytic and macrophage chemo-attractant cytokines etc).

With patients isolated by these aberrant lab values, the window may be narrow but it may be a time where application of antiviral compounds in combination with these inflammatory modulators could have a striking impact on mortality? Indeed maybe even TWO different antivirals with differing mechanisms of action in combination with these S1-PR Agonists would even be better. And the possibilities of other combinations of course would be there for further exploration.

Fully cognizant of the Hippocratic Oath to 'first do no harm' I still believe that at least the medical rationale is sound for the inclusion of these agents into the possible arsenal of therapeutics for the more severe COVID 19 patients.

Please refer below to the studies I found particularly helpful or promising. Perhaps you can put together some 'teams' to further explore investigate these options ??

We all appreciate everything you have done, and continue to do !

Gary Radin

<https://www.sciencedirect.com/science/article/pii/S0140673620303056>

<https://www.pnas.org/content/108/29/12018>

<https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0042682214000063?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0042682214000063%3Fshowall%3Dtrue&referrer=>



Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus | PNAS

Human pandemic H1N1 2009 influenza virus rapidly infected millions worldwide and was associated with significant mortality. Antiviral drugs that inhibit influenza virus replication are the primary therapy used to diminish disease; however, there are two significant limitations to their effective use: ( i ) antiviral drugs exert selective pressure on the virus, resulting in the generation of ...

[www.pnas.org](http://www.pnas.org)

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30566-3/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext)

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study  
- The Lancet

The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 µg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.

[www.thelancet.com](http://www.thelancet.com)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176439/>



Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection - PubMed Central (PMC)

Cytokine storm during viral infection is a prospective predictor of morbidity and mortality, yet the cellular sources remain undefined. Here, using genetic and chemical tools to probe functions of the S1P 1 receptor, we elucidate cellular and signaling mechanisms important in initiating cytokine storm. While S1P 1 receptor is expressed on endothelial cells and lymphocytes within lung tissue ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 23 Apr 2020 22:47:07 +0000  
**To:** Billet, Courtney (NIH/NIAID) [E]; Greg Folkers (b) (6); Conrad, Patricia (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]  
**Cc:** Barasch, Kimberly (NIH/NIAID) [C]  
**Subject:** FW: Sammies recognition this year – congratulations  
**Attachments:** AFauci, NIH.pcf

Please take a look at this and let us discuss. Thanks.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Max Stier <mstier@ourpublicservice.org>  
**Sent:** Thursday, April 23, 2020 2:57 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>  
**Cc:** Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Sammies <Sammies@ourpublicservice.org>  
**Subject:** Sammies recognition this year – congratulations

Dr. Fauci:

I hope you are healthy and well. The [Partnership for Public Service](#) is honored to inform you that we have selected you as a finalist for the 2020 Samuel J. Heyman [Service to America Medals](#), otherwise known as the Oscars of government service.

You were nominated by Francis Collins for your outstanding career at NIAID and the work you are currently doing on behalf of the American people to prepare, inform and protect lives in our country and around the world during this uncertain time. Your work truly embodies the best of government that we strive to recognize through the Sammies program.

Attached, I've included the profile we have drafted to summarize your work and accomplishments – both for recognizing you as a finalist and for having the selection committee vote for the award

recipients. Should you have any edits or wish to add a personal quote, please send those to us at your convenience. We will be releasing your profile publicly with the rest of the finalists on Sunday, May 3.

Again, thank you for the work you do on behalf of the NIH and our country.

Best,

Max Stier  
President and CEO  
Partnership for Public Service

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 23 Apr 2020 22:37:35 +0000  
**To:** Greg Folkers (b) (6); Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** FW: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

FYI

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Dzau, Victor J. <VDzau@nas.edu>  
**Sent:** Thursday, April 23, 2020 1:49 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
(b) (6)  
(b) (6)  
(b) (6)  
**Cc:** Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6);  
(b) (6)  
(b) (6) 'ben.tinker@cnn.com' <ben.tinker@cnn.com>;  
'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>; 'Neel.Khairzada@turner.com'  
<Neel.Khairzada@turner.com>; 'Tia.Miller@turner.com' <Tia.Miller@turner.com>; (b) (6)  
(b) (6); McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6)  
(b) (6); Mun, Jenny <JMun@nas.edu>; (b) (6)  
**Subject:** RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,

I'm really looking forward to this panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25<sup>th</sup> at 2:00-3:30 pm ET. There is tremendous excitement and enthusiasm, and registration is through the roof.



I am sending this note to do a last minute check to see if there is anything you need from me. I also want to check whether you are planning to use slides. Will you be sending your slides to us to project or use the share screen feature to advance your own slides? Regardless, it would be helpful to me if you could send me your slides for my preparation.

I would greatly appreciate it if you would respond to this email.

Best,  
Victor

PS, (b) (6), my special assistant, will be sending you additional information about the session logistics shortly.

---

**From:** Dzau, Victor J. <VDzau@nas.edu>

**Sent:** Thursday, April 9, 2020 11:01 AM

**To:** Mun, Jenny <JMun@nas.edu>; (b) (6)

**Cc:** (b) (6); Hannon, Emma <EHannon@nas.edu>;

'conradpa@niaid.nih.gov' (b) (6); 'T.MillerdeVega@wellcome.ac.uk'

(b) (6); 'jsi@cepi.net' (b) (6) 'rebeka.yasmin@cepi.net'

(b) (6); 'ben.tinker@cnn.com' <ben.tinker@cnn.com>; 'Amanda.Sealy@cnn.com'

<Amanda.Sealy@cnn.com>; 'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>;

'Tia.Miller@turner.com' <Tia.Miller@turner.com>; (b) (6)

**Subject:** RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear all,

Thank you for agreeing to participate in a special late breaking session on the COVID-19 pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in lieu of a call to prepare for the session.

As you know, this is a 90 minute session which aims to provide our audience with deeper insights into the latest developments in the COVID-19 response. I plan to hold an engaging discussion that covers the whole experience on dealing with this pandemic – from US to international, to preparedness and response, the biology of the virus, the state of diagnostic, treatment and vaccine development, and the importance of communication.

I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.



- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best,  
Victor

---

**From:** Mun, Jenny

**Sent:** Wednesday, April 8, 2020 10:56 AM

**To:** [REDACTED] (b) (6)

**Cc:** Dzau, Victor J. ; [REDACTED] (b) (6) ; Mun, Jenny ; Hannon, Emma ; [REDACTED] (b) (6) ; [REDACTED] (b) (6) 'ben.tinker@cnn.com' ; 'Amanda.Sealy@cnn.com' ; 'Neel.Khairzada@turner.com' ; 'Tia.Miller@turner.com'

**Subject:** NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (<https://www.youtube.com/user/theNASciences>) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. **Please return the signed speaker release form by Monday, April 13.**

Session speakers are asked to connect 30 minutes prior to the session start time (**by Saturday, April 25 at 1:30 pm EDT**) to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases  
Jeremy Farrar, Director, Wellcome Trust  
George F. Gao, Director-General, Chinese Center for Disease Control & Prevention  
Sanjay Gupta, Chief Medical Correspondent, CNN  
Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations  
Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings – such as “sharing your screen” (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

\*\*\*\*\*

Jenny Mun  
Membership Director  
National Academy of Sciences  
[jmun@nas.edu](mailto:jmun@nas.edu)

(b) (6)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 23 Apr 2020 22:36:33 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; [REDACTED] (b) (6); Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]  
**Subject:** FW: New sheet  
**Attachments:** COVID.docx

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: [REDACTED] (b) (6)  
FAX: (301) 496-4409  
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Dani Bolognesi, Ph.D. <[REDACTED] (b) (6)>  
**Sent:** Thursday, April 23, 2020 1:01 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>  
**Cc:** Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>  
**Subject:** FW: New sheet

Hi Tony:

I hesitate to bother you with this as I am sure that you are inundated with requests of this sort over and above everything else you are doing which is truly magnificent. I believe that there is something of potential importance in what is communicated below but you are in the best position to tell me whether it could fit in the toolbox you are assembling for COVID 19 in both the short and longer term. I have to acknowledge our friend Bob Gallo for triggering this

[REDACTED] (b) (4)

Reaching out to you to see if you think this approach has merit. Since your time is so precious, I do not expect you to review this but perhaps you can forward to one of your trusted colleagues.

PPS. Loved the interview with Coach K!

Con un forte abbraccio!

Dani

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 23 Apr 2020 22:25:14 +0000  
**To:** [REDACTED] (b) (6)  
**Subject:** FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC <https://bit.ly/2yynEPf>

I may have already sent this to you, but I do not think so. It is short (6 minutes) but it has a segment that shows me 37 years ago. Yikes!!! You will get a chuckle.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: [REDACTED] (b) (6)  
FAX: (301) 496-4409  
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Barasch, Kimberly (NIH/NIAID) [C] [REDACTED] (b) (6)  
**Sent:** Thursday, April 23, 2020 9:04 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)  
**Subject:** FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC <https://bit.ly/2yynEPf>

Kim Barasch [C]  
Office of the Director  
National Institute of Allergy & Infectious Diseases  
[REDACTED] (b) (6)  
[REDACTED] (b) (6)

---

**From:** Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)>  
**Sent:** Tuesday, April 21, 2020 11:06 PM  
**Subject:** MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC <https://bit.ly/2yynEPf>



**Disclaimer:** Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.



**From:** Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 23 Apr 2020 22:14:31 +0000  
**To:** Fauci, Anthony (NIH/NIAID) [E]  
**Subject:** FW: A proposal to stop COVID-19 and reopen our schools and businesses  
**Attachments:** Scientists\_to\_Stop\_COVID19\_2020\_04\_23\_FINAL.pdf

Email below from David Liu.

Robert W. Eisinger, Ph.D.  
Special Assistant for Scientific Projects  
Immediate Office of the Director  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
31 Center Drive, Room 7A-03  
Bethesda MD 20892  
Telephone (b) (6)  
Email: (b) (6)

---

**From:** David Liu (b) (6)  
**Sent:** Thursday, April 23, 2020 6:01 PM  
**To:** Collins, Francis (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Austin, Christopher (NIH/NCATS) [E] (b) (6)>; Wholley, David (FNIH) [T] (b) (6)>; Freire, Maria (FNIH) [T] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6)>  
**Cc:** Michael Rosbash (b) (6)>; Ramnik Xavier (b) (6)>; EDWARD SCOLNICK (b) (6); Stuart Schreiber (b) (6)>; Michael Z Lin (b) (6)>; Ben Cravatt (b) (6)>; Thomas Cahill (b) (6)  
R. Scott Kemp (b) (6)  
**Subject:** Re: A proposal to stop COVID-19 and reopen our schools and businesses

Dear Francis, Anthony, Cliff, Christopher, David, Maria, and Lawrence,

I hope you are all well. Attached is the updated set of four proposals on:

- 1) Rapid repurposing of antiviral drugs to treat COVID-19;
- 2) Expedited development of neutralizing monoclonal antibodies to treat COVID-19;
- 3) Rapid COVID-19 vaccine development;
- 4) Risk-reduced ways to reopen schools and businesses, and the healthcare system changes that are needed to enable them.

We hope you find these updated proposals useful, and would be happy to engage in any way that could be helpful.

Sincerely yours,

Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT), Michael Lin (Stanford), David Liu (Harvard/Broad), Michael Rosbash (Brandeis), Stuart Schreiber (Harvard/Broad), Ed Scolnick (Broad), Jonathan Simons (PCF), and Ramnik Xavier (MGH/Broad)

---

David R. Liu  
Richard Merkin Professor and Director of the Merkin Institute  
of Transformative Technologies in Healthcare  
Director of the Chemical Biology and Therapeutic Sciences Program  
Core Institute Member and Vice-Chair of the Faculty, Broad Institute  
Investigator, Howard Hughes Medical Institute  
Thomas Dudley Cabot Professor of the Natural Sciences  
and Professor of Chemistry & Chemical Biology, Harvard University  
75 Ames Street  
Cambridge, MA 02142

On Apr 19, 2020, at 8:48 PM, Collins, Francis (NIH/OD) [E] (b) (6) wrote:

Dear David et al.,

Thanks for forwarding this very thoughtful document, which presents a series of important recommendations – most of which I agree with. I don't know if you saw Friday's announcement (attached) of the new public private partnership called ACTIV (for Accelerating COVID-19 Therapeutic Interventions and Vaccines), but it has taken on most of the points you raise in sections 1 – 3 of your letter. I share your hopes that remdesivir will show benefit, and the current large NIH-sponsored RCT has completed enrollment and should reveal results in about a month. But of course we want to test multiple other interventions – both small molecules and antibody-based therapies, so we need our trial system to be optimized like never before. I will share your letter with the leaders of ACTIV, who are working with unprecedented speed to prioritize the next set of therapeutic candidates as well as pushing vaccine development programs to adopt exceptionally creative trial designs to test safety and efficacy (with full engagement by FDA).

Best regards, Francis

---

**From:** David Liu (b) (6)  
**Sent:** Sunday, April 19, 2020 5:20 PM  
**To:** OD Labc (NIH/OD) (b) (6); Collins, Francis (NIH/OD) [E] (b) (6)  
**Cc:** Michael Rosbash (b) (6); Ramnik Xavier (b) (6); EDWARD SCOLNICK (b) (6); Stuart Schreiber <(b) (6)>; Michael Z Lin (b) (6); Ben Cravatt (b) (6)  
**Subject:** A proposal to stop COVID-19 and reopen our schools and businesses



Dear Francis,

I hope you are well.

I write on behalf of a group of citizen-scientists, most or all of whom you know. Motivated solely by our desire to help defeat the serious threat our nation and the world now faces, we wrote a set of four actionable, non-partisan proposals (attached) to produce safe and effective COVID-19 therapeutics and vaccines in the shortest possible timeframe, and to reopen our society in a manner that reduces the risk of future COVID-19 outbreaks.

We hope you find these ideas interesting, and might be willing to share this set of proposals with Dr. Tony Fauci, along with our willingness to discuss any part of the proposals with him if we can be helpful. We understand from our efforts to contact Dr. Fauci through email routes that his standard inbox may be too overwhelmed for our proposal to reach him.

The four proposals attached describe: (1) How to rapidly repurpose an antiviral drug to treat COVID-19 patients; (2) How to expedite the development of human antibody drugs to treat patients and to provide short-term protection for healthy individuals; (3) How to develop COVID-19 vaccines on an expedited time scale; and (4) How to reopen our businesses and schools in a manner that reduces the risk of future outbreaks and deaths.

Thank you for any help or thoughts you might be able to provide.

Sincerely yours,

Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT), Michael Lin (Stanford), David Liu (Harvard/Broad), Michael Rosbash (Brandeis), Stuart Schreiber (Harvard/Broad), Ed Scolnick (Broad), Jonathan Simons (PCF), and Ramnik Xavier (MGH/Broad)

---

David R. Liu  
Richard Merkin Professor and Director of the Merkin Institute  
of Transformative Technologies in Healthcare  
Director of the Chemical Biology and Therapeutic Sciences Program  
Core Institute Member and Vice-Chair of the Faculty, Broad Institute  
Investigator, Howard Hughes Medical Institute  
Thomas Dudley Cabot Professor of the Natural Sciences  
and Professor of Chemistry & Chemical Biology, Harvard University  
75 Ames Street  
Cambridge, MA 02142

<NIH\_ACTIV\_Release\_041720.docx>

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 23 Apr 2020 21:47:13 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Cc:** Barasch, Kimberly (NIH/NIAID) [C]  
**Subject:** FW: White House Coronavirus Task Force Meeting - 4.24.20

FYI

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 23 Apr 2020 21:40:33 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Cc:** Barasch, Kimberly (NIH/NIAID) [C]  
**Subject:** FW: Update: White House Coronavirus Task Force Meeting

Heads-up! Change in schedule for tomorrow.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 23 Apr 2020 21:29:50 +0000  
**To:** Fauci, Anthony (NIH/NIAID) [E]  
**Subject:** FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC <https://bit.ly/2yynEPf>

<https://bit.ly/2yynEPf>

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Barasch, Kimberly (NIH/NIAID) [C] (b) (6)  
**Sent:** Thursday, April 23, 2020 9:04 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC <https://bit.ly/2yynEPf>

Kim Barasch [C]  
Office of the Director  
National Institute of Allergy & Infectious Diseases  
(b) (6)  
(b) (6)

---

**From:** Folkers, Greg (NIH/NIAID) [E] (b) (6) >  
**Sent:** Tuesday, April 21, 2020 11:06 PM  
**Subject:** MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC <https://bit.ly/2yynEPf>



**Disclaimer:** Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

**From:** (b) (6)  
**Sent:** Thu, 23 Apr 2020 14:34:36 -0400  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** Fwd: Thank you, and...  
**Attachments:** image002.png, ATT00001.htm, PasstheMic Expert Outreach.pdf, ATT00002.htm

Let us discuss

Begin forwarded message:

**From:** Gayle Smith <gayle.smith@one.org>  
**Date:** April 23, 2020 at 1:49:04 PM EDT  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)  
**Cc:** Tom Hart <tom.hart@one.org>  
**Subject:** Thank you, and...

Dear Tony,

I have always felt reassured when the good Dr. Fauci speaks, and now more than ever. As an American, a former colleague, a long-time admirer and student of your wisdom – thank you. We are all safer because of you, and the world will be a better place because of you. Again.

As you know, I am now leading the ONE Campaign. We've been quite active with the ONEWorld Campaign, dedicated to the fight against this newest virus, and focused on Africa. We've made some progress on debt, and next up is a focus on ensuring that a vaccine, when it comes, is available to everyone.

One of the things we want to do is educate people, in all of the places we work. It won't surprise you that of particular urgency amongst our partners in Africa is that facts and information get to people across the continent, but we also know that more facts are needed everywhere. So next month we are going to launch #PassTheMic, where every day for 19 days we will ask a celebrity to turn his or her social media channels over to an expert on COVID-19 for one day. So Julia Roberts might turn her Twitter account to you to talk about the critical elements needed to flatten the curve and slow the spread. Or Idris Elba could give up his Instagram to the head of the African CDC so that he can illustrate the impact COVID-19 will have across Africa and what that means for the rest of the world.

We know artists want to be helpful right now, but that it is hard to know what to do. And we know there are experts like you out there who have the answers. We've thought about this a lot at ONE and wanted to do something we felt would truly have an impact. As we look ahead we know COVID-19 does not know borders and until it is beaten everywhere

we are not in the clear. We need a global response plan and we need it now. By turning over their platforms for the day, celebrity influencers will be donating one of their biggest assets – their followers – to YOU, giving you the platform you need (and we all need) to tell the world why a global response is critical. Because none of us are safe until all of us are safe.

We will work with each expert/celebrity pair to personalize the content to our and our celebrity partners' audiences – in North America, Europe and Africa, and help create content that both parties are happy with. We are now confirming our talent partners, and so far are getting a terrific response.

We know you're a busy man, so we've planned it so that the amount of time on your end would be minimal. But the impact would be maximal.

I'm attaching more information about the campaign. Please let me know what you think and if you have questions. Ideally we would like to get this off the ground in early May, so are hoping to confirm folks by April 28th at the latest. Our team will be in touch with your office to follow up.

Thanks as always for everything you do. All my best to you, Gayle





ONE

**Gayle Smith** | President & Chief Executive Officer | (b) (5)

[ONE.ORG](#) | [Twitter](#) | [Facebook](#) | [Instagram](#)

ONE is a global movement campaigning to **end extreme poverty and preventable disease by 2030** so that everyone, everywhere can lead a life of dignity and opportunity.

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 23 Apr 2020 18:25:56 +0000  
**To:** Simmons-Butler, Kirk (NIH/NIAID) [C]  
**Subject:** Re: Thank you Dr. Fauci!  
**Attachments:** image001.png, image002.gif

Kirk:

Thank you for your kind note. Much appreciated.  
Best regards,  
Tony

On Apr 23, 2020, at 2:16 PM, Simmons-Butler, Kirk (NIH/NIAID) [C]  
(b) (6) wrote:

Greetings Dr. Fauci,

I just wanted to take a moment to personally thank you for all of your support and leadership during these unprecedented times. I am proud to be a part of the NIAD family and you represent us and the country well! God continue to bless and keep you and your family! Thank you again sir!

Regards,  
Kirk

Kirk D. Simmons-Butler, M.S.  
Assistant Facility Manager 14DNR, Charles River Laboratories Inc.  
NIH/NIAID  
(Office) (b) (6)  
(Fax) (301) 761-6013  
Charles River website - [www.criver.com](http://www.criver.com)

<image001.png>

<image002.gif>

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it

from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Disease (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Sent:** Friday, March 27, 2020 11:55 AM  
**To:** NIAID Announcements <NIAID-announce@niaid.nih.gov>  
**Subject:** Platelet Donations Down are Down Amid Coronavirus Outbreak – Please Donate

Dear Colleagues:

The NIH Platelet Donor Center has an urgent need for healthy individuals to give lifesaving platelets to patients. The need for platelet donations is especially acute now with the coronavirus pandemic. While social distancing and increased telework are necessary to contain and slow the spread of coronavirus, we have seen a marked decline in platelet and blood donations for our patients.

To alleviate this shortage, NIAID and the Department of Transfusion Medicine (DTM) are co-sponsoring a two-week Platelet Drive from March 30 – April 10. Platelet collections, as well as whole blood and Double Red Cell donations, can only be made at the NIH Blood Bank on campus in Building 10, Room 1C713 Monday through Friday from 8:00 am to 5:00 pm. The Platelet Center at Fishers Lane is temporarily closed and platelet collections are now on the main campus through at least the next 30 days. This move helps to ensure that blood donors are protected by visitor screening, minimizing possible exposure to individuals at risk.

What is a double red cell donation? A double red cell donation enables donors to donate two units of red blood cells in one visit. During a procedure called apheresis, whole blood is separated through a cell separator and red blood cells are collected. The remainder of the blood components are returned to the donor along with saline to replace the lost volume.

I encourage participation of all employees who are eligible to provide a donation to benefit our NIH patients. I understand employees may be hesitant to participate under the current conditions, but I would like to reassure you that blood donation is a safe process.

Additional precautions have been put in place at our Blood Bank to help prevent the spread of infection and protect the health of donors and staff.

Thank you to all who support our quarterly platelet drives. Your efforts provide a lifeline for our patients. Those who participated in the last drive are now eligible to help once again. In appreciation of your dedication to helping others, NIAID grants administrative leave to any NIAID federal employee who donates platelets at the NIH Blood Bank. Specifically, you will be granted 4 hours of administrative leave to be used immediately following your platelet donation appointment. As always with such activities, please notify your supervisor for approval prior to donating at the NIH Platelet Center.. Contractor employees should speak directly to their contract companies to determine what leave

options are available. Please contact the Donor Center at [301-496-4321](tel:301-496-4321) to schedule your appointment. Let the Donor Center staff know you are with the NIAID Platelet/Double Red Cell Drive. They will answer eligibility questions and provide information about the donation process.

Thank you for considering donating during this stressful time. Best regards.

Sincerely,  
A.S. Fauci

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.





**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 23 Apr 2020 17:39:48 +0000  
**To:** Auchincloss, Hugh (NIH/NIAID) [C] [REDACTED] (b) (6)  
**Subject:** FW: Wellness Initiative Proposal  
**Attachments:** Wellness Initiative\_POC\_Sundar.zip, Wellness Initiative Proposal\_Sundar.pdf, Managing Anxiety Around COVID-19 March 27 (007).pdf

Please take a look at this and handle.

---

**From:** Sundar, Sachin (NIH/NIAAA) [F] [REDACTED] (b) (6) >  
**Sent:** Thursday, April 23, 2020 1:05 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >  
**Subject:** Wellness Initiative Proposal

Dear Dr. Fauci,

I have an idea regarding science communication and wellness. Here's a rough proposal and proof of concept. At full effect, I think it could have noteworthy potential. [REDACTED] (b) (5)

[REDACTED]

Thank you for your time.

Respectfully,  
Sachin Sundar

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 23 Apr 2020 13:25:22 +0000  
**To:** Stephen L. Hoffman  
**Subject:** RE: Follow Up Thanks

Thanks, Steve. I appreciate your note.  
Best regards,  
Tony

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Stephen L. Hoffman <slhoffman@sanaria.com>  
**Sent:** Wednesday, April 22, 2020 9:56 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** Follow Up Thanks

Dear Tony,

I hear continuously from people from all walks of life how grateful they are for your presence on the COVID-19 team. You are performing an incredible service to our country and the world.

Thanks again,

Steve

Stephen L. Hoffman, M.D.  
Chief Executive and Scientific Officer  
Sanaria Inc.  
9800 Medical Center Dr. ste 209a  
Rockville MD 20850  
tel: (b) (6) (work)



tel: (b) (6)(mobile)  
fax: 301-770-5554  
E-Mail: [slhoffman@sanaria.com](mailto:slhoffman@sanaria.com)  
[www.sanaria.com](http://www.sanaria.com)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 23 Apr 2020 13:00:55 +0000  
**To:** Redfield, Robert R. (CDC/OD)  
**Cc:** Allison Arwady;David Barr;Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** FW: Dr. Fauci asked me to send Chicago question  
**Attachments:** Workforce\_Proposal\_Chicago\_April2020.pdf

Bob:

Please take a look at this. This question evolved from a teleconference that I had 2 nights ago with people "in the trenches" including Alison Arwady (Chicago). The question is what will be the relationship between the public health workforces at the federal and local levels. You had spoken of the CDC people that will be assigned locally and that will help build up a local workforce. How will CDD interact and relate to the locals. Is there any possibility of Federal funding of their proposal (see attachment). If not, do you have any suggestions for them? I can discuss this with you today at the Task Force meeting. Thanks.

Best,  
Tony

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>  
**Sent:** Wednesday, April 22, 2020 3:53 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** FW: Dr. Fauci asked me to send Chicago question

Pls advise.

---

**From:** Allison Arwady <[REDACTED] (b) (6)>  
**Sent:** Wednesday, April 22, 2020 3:42 PM  
**To:** Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>  
**Subject:** Dr. Fauci asked me to send Chicago question

Dear Patty,

Last night on his call with public health leaders from cities across the country, Dr. Fauci asked me to send him/you my follow-up question from Chicago:

**How will the necessary public health workforce expansion (e.g. for wide-scale case investigation, contact tracing, linkage to care, community testing, and vaccination) be supported at the federal level?**

Our understanding is that state or local jurisdictions will be able to develop their own workforces rather than supporting a single workforce at the federal level, and we agree with this approach, but it would be very helpful to understand next steps and potential timelines, particularly as the reopening drumbeat gets louder.

For example, Chicago has developed a local plan/proposal (attached) that would meet our local needs, help address some of our underlying race and economic equity concerns, and build on our existing community and clinical partnerships. We have shared it with some partners, but it is not at all clear how/whether/when/how much funding might be available. Given the need to quickly expand our workforce and plan ahead, it would be very helpful to get a sense of:

- a. How much funding/support might be available, and how that will be determined
- b. Whether funding might come through HHS/CDC (our preferred mechanism), FEMA, or another mechanism
- c. Will support be available in weeks or months...and for how long—we are strongly advocating for 5 years, similar to what was done for Ebola
- d. Any other information about how our local or state plans need to be adapted to fit into federal thinking on this approach

Thank you so much; I deeply appreciate Dr. Fauci taking the time to meet with us directly and hear our concerns.

Allison

**Allison Arwady, MD, MPH**  
Commissioner  
Chicago Department of Public Health

[REDACTED] (b) (6)



**From:** David Barr (b) (6)  
**Sent:** Wednesday, April 22, 2020 8:47 AM  
**To:** Allison Arwady (b) (6); Percak, Jeffrey M (b) (6); Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Demetre Daskalakis (b) (6); Mushatt, David M (b) (6); Barasch, Kimberly (NIH/NIAID) [C] <(b) (6)>; Iyengar, Preetha (DOH) (b) (6)  
Duchin, Jeff (b) (6)  
**Subject:** Notes from call with Dr. Fauci

Hello - Thanks for all for a very informative and sobering discussion last night. I've provided bullets below to capture the main points. Please add or change as needed. I've kept this relatively short but can supply a full recording of the call if you want it.

We will have another call next Tuesday.

David

#### PPE supplies:

- while hospitals are in better shape than a few weeks ago, significant shortages remain at long-term care facilities, skilled nursing facilities, outpatient settings like doctors' offices and urgent care clinics, shelters, prisons. Gowns are the biggest problem, but gloves, masks and shields are also short. Doctors offices are closing for lack of PPE.
- each city is trying to solve these shortages in a short-term, piecemeal way. They need a longer-term solution to stabilize availability. Outpatient settings are looking to health departments to provide supplies, something HDs are not set up to do.
- testing in most places still requires PPE use (e.g. no availability of anterior nasal swabs) and the PPE shortages are severely limiting testing scale up.
- even at hospitals, supply limitations make re-opening elective surgeries and other procedures impossible at this stage.
- If considering re-opening businesses, this will drastically increase PPE needs to a whole new sector.

#### TESTING challenges:

- Each city reported that, despite improvements, a very limited number of tests are being performed compared to need.
- Supply shortages are the biggest challenge: swabs, PPE, sample kits, reagents are the biggest obstacles. Not clear where this is going to come from or who is responsible for addressing problems.
- Private labs limit number of sample kits distributed each week. In places where public labs are available, there is a push to get providers to use the public labs. But many places don't have public labs.
- There is no clear guidance on how to prioritize who gets tested first. So, in some places, that means that people at lower-risk are being tested but people at greater risk (due to symptoms,

exposure, high-risk living/work environment, etc) are not being testing. Guidelines are needed to help prioritize where testing resources are used first.

- Public testing produces skewed results. Testing becomes available only to those who can make an appointment and who can drive to the site. This means many lower-priority people get tested but high-priority people do not. This skews understanding of positivity rates.

- Some labs are underutilized - but the reason is that there are breakdowns in the supply chain that make it difficult to test people and get tests to the labs. (e.g.) [REDACTED] (b) (4)

- Reimbursement is an obstacle. CMS offering to cover test costs (\$100 per test) would help get labs to do more testing. It would not solve the problem, but it would help.

- Proliferation of unvalidated antibody tests is causing confusion. High rates of false results, misinterpretation of what results mean (e.g. telling people who test antibody positive that they must quarantine for two weeks). Chicago spends a lot time shutting down these testing sites as they make things harder and use up supplies.

- there is increasing pressure to reach a target number of tests performed each day in order to get to 're-opening'. But the number needed is contextual based on the environment, population - there isn't one 'right' number for everywhere.

- Need better public messaging on difference between virology and serologic tests.

- Current testing capacity is no where near what is needed to make informed decisions about re-opening.

#### TESTING: reporting challenges

- Current PoC tests have no link to provide results to health departments. Many outpatient facilities and SNFs have no system for reporting test results to HDs. Need electronic link for reporting PoC test results.

- While aggregate positive tests may be reported, negative results are not.

- Impossible to really understand population levels of infection because (1) number of tests performed is too low and (2) not testing the 'right' people

- Every one is pushing for rapid scale up of antibody tests, but we still don't know what the results of these tests mean and how to apply them to policy development.

- CDC and NIH will each coordinate sero-surveys. No details on CDC approach yet. NIH study is up. Still not clear how to use the results of these studies, but useful to collect data now and apply it as knowledge grows. Locally-coordinate sero-surveys can be helpful but only if tests are highly validated.

#### The Future:

- How many tests should we be doing? How much PPE/testings/beds/staff will be needed in the coming year? Next winter, we will face dual flu and COVID outbreaks, without stable testing capacity, how will we differentiate between the two?

- What are the plans for contact tracing? Who will recruit and train? Is there a federal plan or guidelines for this? How will it be paid for? What do we do to effectively isolate those infected?

---

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail (or the person responsible for delivering this document to the intended recipient), you are hereby notified that any dissemination, distribution, printing or copying of this e-mail, and any attachment thereto, is strictly prohibited. If you have received this e-mail in error, please respond to the individual sending the message, and permanently delete the original and any copy of any e-mail and printout thereof.



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 23 Apr 2020 12:53:24 +0000  
**To:** Stover, Kathy (NIH/NIAID) [E]  
**Cc:** Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** RE: FOR ASF REVIEW: Draft PR re: launch of hydroxychloroquine/azithromycin study

Looks fine.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Stover, Kathy (NIH/NIAID) [E] (b) (6)  
**Sent:** Wednesday, April 22, 2020 3:56 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Cc:** Billet, Courtney (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>  
**Subject:** FOR ASF REVIEW: Draft PR re: launch of hydroxychloroquine/azithromycin study

Hi Dr. Fauci,

Please find attached for your review a draft press release describing the launch of the ACTG hydroxychloroquine/azithromycin study for COVID-19. NIAID will issue the release after the first participant(s) has enrolled, which is currently anticipated around May 1.

The following is the quote we have drafted for you:

"We urgently need a safe and effective treatment for COVID-19. Repurposing existing drugs is an attractive option because these medications have undergone extensive testing, allowing them to move quickly into clinical trials and accelerating their potential approval for COVID-19 treatment," said NIAID Director Anthony S. Fauci, M.D. "Although there is anecdotal evidence

that hydroxychloroquine and azithromycin may benefit people with COVID-19, we need solid data from a large randomized, controlled clinical trial to determine whether this experimental treatment is safe and can improve clinical outcomes.”

Thanks much,  
Kathy

Kathy Stover  
Branch Chief  
News and Science Writing Branch  
National Institute of Allergy and Infectious Diseases (NIAID)  
Office of Communications and Government Relations  
National Institutes of Health/HHS  
31 Center Drive, Room 7A17E  
Bethesda, MD 20892  
Phone: (b) (6)  
E-mail: (b) (6)  
NIAID Media Line: (301) 402-1663



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 23 Apr 2020 11:54:41 +0000  
**To:** Corey MD, Larry (b) (6); Mascola, John (NIH/VRC) [E]  
**Cc:** Conrad, Patricia (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]  
**Subject:** NEJM manuscript  
**Attachments:** COVID vaccine editorial\_prefinal April21\_7pm fsc - with minor Fauci edits.docx

Larry/John:

I have gone over the changes that Francis has inserted and I have edited some of them. Please accept his changes and my edits of them (or any additional edits that you have) and then it is OK to send in. Please let me know if you have any questions.

Thanks,  
Tony

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.